The path to glucose health begins with trusting your gut

DayTwo is the leading microbiome-based precision medicine company, offering personalized nutrition and therapeutic solutions using artificial intelligence and machine learning algorithms. DayTwo has the largest full-shotgun DNA sequencing database of the gut microbiome in the world. The Company leverages its Gut Microbiome Platform™ to conduct advanced genetic sequencing of gut microbiome and big data analytics to predict an individual’s glycemic response based on gut microbiome and other clinical parameters. DayTwo translates this data into personalized, actionable insights primarily aimed to prevent and treat metabolic diseases such as diabetes and obesity.

Investing partner / fund: